February 2015

10th Annual Parallel Trade  8th February to 9th February 2016, London, United Kingdom

SMi's premier 10th Annual Parallel Trade for Pharma returns to London on 8-9 Feb 2016 after 9 successful years in the running!

Parallel distribution market in 2015 has been an interesting year: foreign exchange fluctuations, Greek crisis, tightened export control, legal battles on trademarks and counterfeit medicines. These, in addition to many other factors, have shifted the European market dynamics significantly.

Market participants continue to innovate new strategies to ensure revenue stream, but more importantly compliant of safety and accessibility of drugs for patients. The pressure of uncertainty is prompting industry colleagues to rethink and reassess their current supply chain models.

What new opportunities will present to parallel distribution in 2016? How should pharma and manufacturers perfect their sales and supply chain forecast? Will the EU Falsified Medicine Directive in 2018 reassure patient safety?

This is the only industry meeting with 80+ selected senior leaders in parallel trade to discuss upcoming trends and share best practices. Join us today to keep abreast and stay ahead of competition!

10th Annual Parallel Trade  8th February to 9th February 2016, London, United Kingdom

SMi's premier 10th Annual Parallel Trade for Pharma returns to London on 8-9 Feb 2016 after 9 successful years in the running!

Parallel distribution market in 2015 has been an interesting year: foreign exchange fluctuations, Greek crisis, tightened export control, legal battles on trademarks and counterfeit medicines. These, in addition to many other factors, have shifted the European market dynamics significantly.

Market participants continue to innovate new strategies to ensure revenue stream, but more importantly compliant of safety and accessibility of drugs for patients. The pressure of uncertainty is prompting industry colleagues to rethink and reassess their current supply chain models.

What new opportunities will present to parallel distribution in 2016? How should pharma and manufacturers perfect their sales and supply chain forecast? Will the EU Falsified Medicine Directive in 2018 reassure patient safety?

This is the only industry meeting with 80+ selected senior leaders in parallel trade to discuss upcoming trends and share best practices. Join us today to keep abreast and stay ahead of competition!

Parallel Trade 9h February to 10th February 2015, London, United Kingdom

Pharmaceutical Parallel Trade in the European Union is a large and growing phenomenon.

Different regulatory regimes for pharmaceuticals result in significant differences in pharmaceutical prices across countries. These prices make it profitable for Parallel Trade to take place in addition to PT reaching a significant proportion of total national pharmaceutical expenditure in many European countries, particularly those with high pharmaceutical prices such as UK, Germany, the Netherlands and Sweden. But the issue of pharmaceutical Parallel Trade continues to generate controversy among stake holders and has become an issue of intense debate in the global trading system.

Europe’s leading Parallel Trade Conference will focus on assessing pricing strategies and the impact of parallel trade on the generics market and vice versa. In addition, there will be three open floor round table discussions drawing attention to the ongoing debate; is parallel trade justified? Stakeholder engagement and competition law effects will be discussed, in addition to a breakfast briefing on assessing data collection… and that’s just to start with.

Patient safety is first and foremost when it comes to the implementation of the Anti-Counterfeit Directive and this will be addressed. What will follow is assessing the repackaging and re-boxing of products. Further topics to be evaluated include case studies on the implementation of best practices and the outcomes to be reviewed on parallel trade, are they positive or negative?

The note to end on will be… What’s the future of Parallel Trade?

Parallel Trade 9h February to 10th February 2015, London, United Kingdom

Pharmaceutical Parallel Trade in the European Union is a large and growing phenomenon.

Different regulatory regimes for pharmaceuticals result in significant differences in pharmaceutical prices across countries. These prices make it profitable for Parallel Trade to take place in addition to PT reaching a significant proportion of total national pharmaceutical expenditure in many European countries, particularly those with high pharmaceutical prices such as UK, Germany, the Netherlands and Sweden. But the issue of pharmaceutical Parallel Trade continues to generate controversy among stake holders and has become an issue of intense debate in the global trading system.

Europe’s leading Parallel Trade Conference will focus on assessing pricing strategies and the impact of parallel trade on the generics market and vice versa. In addition, there will be three open floor round table discussions drawing attention to the ongoing debate; is parallel trade justified? Stakeholder engagement and competition law effects will be discussed, in addition to a breakfast briefing on assessing data collection… and that’s just to start with.

Patient safety is first and foremost when it comes to the implementation of the Anti-Counterfeit Directive and this will be addressed. What will follow is assessing the repackaging and re-boxing of products. Further topics to be evaluated include case studies on the implementation of best practices and the outcomes to be reviewed on parallel trade, are they positive or negative?

The note to end on will be… What’s the future of Parallel Trade?

RNA Therapeutics  15th February to 16th February 2016, London, United Kingdom

The 2016 RNA Therapeutics conference will hone in on some key developments currently shaping the industry, and putting the spotlight on messenger RNA-based Therapeutics.

We will review clinical trial updates in oncology, cardiovascular injury, and ophthalmology, and open the floor for discussion to review existing and emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates as well as messenger RNA therapeutics.

The biggest challenge in enabling RNAi therapy is transporting RNA to target sites outside the liver, and so having targeted delivery systems, which can optimise bioavailability and controllable kinetics remains an issue. However, with exciting concepts such as polymeric nanoparticles and viral vectors as a new class of carriers existing on the horizon, the conference will look at the future of these technologies.

Moreover, messenger RNA (mRNA) is attracting considerable interest for its ability to restore gene expression and correct protein production. Thus, we will anticipate what new avenues will open up in gene- based therapies.

RNA Therapeutics  15th February to 16th February 2016, London, United Kingdom

The 2016 RNA Therapeutics conference will hone in on some key developments currently shaping the industry, and putting the spotlight on messenger RNA-based Therapeutics.

We will review clinical trial updates in oncology, cardiovascular injury, and ophthalmology, and open the floor for discussion to review existing and emerging concepts in delivery systems, oligonucleotides, aptamer-conjugates as well as messenger RNA therapeutics.

The biggest challenge in enabling RNAi therapy is transporting RNA to target sites outside the liver, and so having targeted delivery systems, which can optimise bioavailability and controllable kinetics remains an issue. However, with exciting concepts such as polymeric nanoparticles and viral vectors as a new class of carriers existing on the horizon, the conference will look at the future of these technologies.

Moreover, messenger RNA (mRNA) is attracting considerable interest for its ability to restore gene expression and correct protein production. Thus, we will anticipate what new avenues will open up in gene- based therapies.

Advances and Progress in Drug Design 16th February to 17th February 2015, London, United Kingdom

SMi are proud to present the 14th Annual Advances and Progress in Drug Design Conference, convening in Central London on Monday 16 and Tuesday 17 February 2015.

The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. Drug design involves the designing of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design, is the inventive process of finding new medications based on the knowledge of the biological target.

As science and technology is advancing, drug designing has moved from traditional methods to advanced methods like computer aided drug designing and computational techniques. This informative event will focus on the recent developments and growth drivers in drug design.

High profile scientists from pharma companies and biotech organizations will be speaking about structure based drug designing, fragment based drug designing, computer based drug designing, pharmacokinetics, polypharmacology and metabolism in drug designing

RNA Therapeutics 16th February to 17th February 2015, London, United Kingdom

Selective inhibition of gene expression by RNA interference (RNAi) and wider oligonucleotide methods hold the potential to address significant unmet medical needs with importance across major disease areas such as cancer, genetic disorders, cardiovascular disease and autoimmune disorders.  Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation and positioning in the market place.

This conference offers the opportunity to engage with strategies for advancing RNAi–based therapies for rare and major diseases through development and clinical trials to market, case study updates on approaches to optimizing RNAi formulation and delivery and hear lessons learned through successful submissions from regulators.

Advances and Progress in Drug Design 16th February to 17th February 2015, London, United Kingdom

SMi are proud to present the 14th Annual Advances and Progress in Drug Design Conference, convening in Central London on Monday 16 and Tuesday 17 February 2015.

The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. Drug design involves the designing of small molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design, is the inventive process of finding new medications based on the knowledge of the biological target.

As science and technology is advancing, drug designing has moved from traditional methods to advanced methods like computer aided drug designing and computational techniques. This informative event will focus on the recent developments and growth drivers in drug design.

High profile scientists from pharma companies and biotech organizations will be speaking about structure based drug designing, fragment based drug designing, computer based drug designing, pharmacokinetics, polypharmacology and metabolism in drug designing

RNA Therapeutics 16th February to 17th February 2015, London, United Kingdom

Selective inhibition of gene expression by RNA interference (RNAi) and wider oligonucleotide methods hold the potential to address significant unmet medical needs with importance across major disease areas such as cancer, genetic disorders, cardiovascular disease and autoimmune disorders.  Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation and positioning in the market place.

This conference offers the opportunity to engage with strategies for advancing RNAi–based therapies for rare and major diseases through development and clinical trials to market, case study updates on approaches to optimizing RNAi formulation and delivery and hear lessons learned through successful submissions from regulators.

Discovery Chemistry Congress, 17-18 February 2015, Berlin, Germany

Featuring an array of leading international speakers, the 11^th annual meeting aims to provide an insight into the latest developments in Discovery Chemistry.

Hot topics to be covered include Fragment Based Lead Discovery, DOS & Other Chemistries and Protein-protein Interactions. Attending this event will provide excellent opportunities for networking with like-minded peers, helping you to find solutions and build collaborations. The agenda is available to view online.

A co-loated exhibition will cover the latest technological advances and associated services from leading solution providers within this field.

Screening Europe, February 17-18 2015 Berlin, Germany

Screening Europe is back! After a break of four years during which we covered screening topics within the European LabAutomation event, SELECTBIO is delighted to re-introduce this popular conference.

Hot topics to be covered include 3D cell based screening methods, the use of model organisms, and novel approaches for data analysis. Focus will also be given to the evolving use of phenotypic screening. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.

Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Discovery Chemistry Congress, ensuring a cost effective trip.

Discovery Chemistry Congress, 17-18 February 2015, Berlin, Germany

Featuring an array of leading international speakers, the 11^th annual meeting aims to provide an insight into the latest developments in Discovery Chemistry.

Hot topics to be covered include Fragment Based Lead Discovery, DOS & Other Chemistries and Protein-protein Interactions. Attending this event will provide excellent opportunities for networking with like-minded peers, helping you to find solutions and build collaborations. The agenda is available to view online.

A co-loated exhibition will cover the latest technological advances and associated services from leading solution providers within this field.

Screening Europe, February 17-18 2015 Berlin, Germany

Screening Europe is back! After a break of four years during which we covered screening topics within the European LabAutomation event, SELECTBIO is delighted to re-introduce this popular conference.

Hot topics to be covered include 3D cell based screening methods, the use of model organisms, and novel approaches for data analysis. Focus will also be given to the evolving use of phenotypic screening. Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.

Running alongside the conference will be an exhibition covering the latest technological advances and associated services from leading solution providers within this field. Registered delegates will also have access to the co-located Discovery Chemistry Congress, ensuring a cost effective trip.

8th Pharmacovigilance 2015 24th & 25th February 2015, Marriott Marble Arch Hotel, London, UK

8th Annual Pharmacovigilance 2015 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  The entire program will cover the detection, analysis and prevention of adverse drug reactions.  It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisations' compliance with pharmacovigilance requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.

KEY THEMES:-

• Update yourself with respect to terms of legislation, policies, systems, technology, communication strategies and best practice in PV
• Developing Pharmacovigilance into high quality management system and its components
• Audit and Inspection: Realistic steps for a fruitful consequence
• EMA PSMF - Assuring compliance and provide standardization
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Exploiting the pharmacy automations and technologies for enhancement of medication safety
• Developments in Pharmacovigilance, drug safety & risk management to ensure safer drugs to market
• Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
• Determining the steps and strategies for enhancing quality in healthcare
• Emerging signal detection data gathering successful tools to highlight emerging risks
• IT solutions for Pharmacovigilance – Learn & Explore
• Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
• GVP Module V and XVI – explaining authority expectations and avoid speculation and differing interpretation of the current guidelines
• Review the use of (PSURs) post-authorisation for safety signals
• ICH-R3 standards - Determining where future challenges could arise
• The developing regulatory framework in advanced and developing markets
• Accelerating new medicine introduction in developing world & overcoming challenges
• Explaining how to use the data sources and observational research for effective safety analysis
• Be part of a major networking opportunity

WHO SHOULD ATTEND:-

• Pharmacovigilance
• Pharmacoepidemiology
• Pharmacogenomics
• Drug/Product Safety
• Drug Development
• Information and Clinical Data Management
• Clinical Pharmacology
• Clinical Safety
• Periodical safety update Reports
• Risk Management
• Research & Development
• Quality Assurance
• Patient Safety
• Signal Detection
• Safety Surveillance
• Outcomes Research
• Data Analysis
• Epidemiology
• Medical Affairs
• Regulatory Affairs and Compliance
• Information technology
• Sales and Marketing

8th Pharmacovigilance 2015 24th & 25th February 2015, Marriott Marble Arch Hotel, London, UK

8th Annual Pharmacovigilance 2015 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  The entire program will cover the detection, analysis and prevention of adverse drug reactions.  It will be studied with the help of case studies and industry experiences. This conference will help the drug safety representatives from the pharmaceutical industry and academic and quality research organisations who wish to understand how to avoid common deficiencies in inspections by learning from the experiences of others; to gain a greater understanding of new and existing pharmacovigilance requirements, and to improve their organisations' compliance with pharmacovigilance requirements. Also it can help you control your product's lifecycle, your patient's trust, and your revenue. Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting pharmacovigilance development.

KEY THEMES:-

• Update yourself with respect to terms of legislation, policies, systems, technology, communication strategies and best practice in PV
• Developing Pharmacovigilance into high quality management system and its components
• Audit and Inspection: Realistic steps for a fruitful consequence
• EMA PSMF - Assuring compliance and provide standardization
• Discover approaches for collecting, integrating and analyzing all of the safety data generated from preclinical models
• Exploiting the pharmacy automations and technologies for enhancement of medication safety
• Developments in Pharmacovigilance, drug safety & risk management to ensure safer drugs to market
• Improving patient care and safety in relation to use of medicines and all medical and paramedical interventions
• Determining the steps and strategies for enhancing quality in healthcare
• Emerging signal detection data gathering successful tools to highlight emerging risks
• IT solutions for Pharmacovigilance – Learn & Explore
• Maintaining proper balance in relationships: Sponsor – Site – CRO & Patients
• GVP Module V and XVI – explaining authority expectations and avoid speculation and differing interpretation of the current guidelines
• Review the use of (PSURs) post-authorisation for safety signals
• ICH-R3 standards - Determining where future challenges could arise
• The developing regulatory framework in advanced and developing markets
• Accelerating new medicine introduction in developing world & overcoming challenges
• Explaining how to use the data sources and observational research for effective safety analysis
• Be part of a major networking opportunity

WHO SHOULD ATTEND:-

• Pharmacovigilance
• Pharmacoepidemiology
• Pharmacogenomics
• Drug/Product Safety
• Drug Development
• Information and Clinical Data Management
• Clinical Pharmacology
• Clinical Safety
• Periodical safety update Reports
• Risk Management
• Research & Development
• Quality Assurance
• Patient Safety
• Signal Detection
• Safety Surveillance
• Outcomes Research
• Data Analysis
• Epidemiology
• Medical Affairs
• Regulatory Affairs and Compliance
• Information technology
• Sales and Marketing

Catalyses in Drug Discovery Summit Feb 26-27,2015 San Diego, CA

We are excited to announce the inaugural Catalyses in Drug Discovery Summit, which will take place February 26 - 27, 2015 in San Diego, CA. This summit will feature the following three conferences, which will happen in parallel:

Enzymes in Drug Discovery

Enzymes have proven to be an important group of drug targets in diseases, and enzyme inhibitors have been among the most successful of drugs. Join us as we discuss ways to overcome drug resistance to these inhibitors, and discuss breakthroughs in targeting historically undruggable enzymes.

 

Ubiquitin Research & Drug Discovery

This meeting will discuss how recent structural insights into ubiquitin have opened the door to other possibilities in drug discovery. Researchers will discuss hot topics such as phosphorylation of ubiquitin, particularly in Parkinson's Disease, DUBs as drug targets, and many more.

Protease Inhibitors in Drug Discovery

Proteolytic enzymes have always been on the forefront of cancer research, though scientists in the field are still working to overcome the challenge of specificity in drug design. This meeting will discuss new mechanisms of actions for better specificity and cover hot topics such as exosites, membrane-associated systems, and more.

Catalyses in Drug Discovery Summit Feb 26-27,2015 San Diego, CA

We are excited to announce the inaugural Catalyses in Drug Discovery Summit, which will take place February 26 - 27, 2015 in San Diego, CA. This summit will feature the following three conferences, which will happen in parallel:

Enzymes in Drug Discovery

Enzymes have proven to be an important group of drug targets in diseases, and enzyme inhibitors have been among the most successful of drugs. Join us as we discuss ways to overcome drug resistance to these inhibitors, and discuss breakthroughs in targeting historically undruggable enzymes.

 

Ubiquitin Research & Drug Discovery

This meeting will discuss how recent structural insights into ubiquitin have opened the door to other possibilities in drug discovery. Researchers will discuss hot topics such as phosphorylation of ubiquitin, particularly in Parkinson's Disease, DUBs as drug targets, and many more.

Protease Inhibitors in Drug Discovery

Proteolytic enzymes have always been on the forefront of cancer research, though scientists in the field are still working to overcome the challenge of specificity in drug design. This meeting will discuss new mechanisms of actions for better specificity and cover hot topics such as exosites, membrane-associated systems, and more.